This study tests a new treatment for people with stage IV metastatic non-small-cell lung cancer (NSCLC). The treatment uses a type of cell called Tumor-Infiltrating Lymphocytes (TILs) made from the patient's own cells. This process is called *autologous* TIL therapy. Patients first get a special medicine to prepare their body, then they receive their own TILs, and finally a medicine called IL-2. The study is for those who have tried other treatments but their cancer still grew.

• **Study Duration**: The length of the study isn't specified, but it involves multiple steps and check-ups.
• **Risks**: Treatment may involve side effects due to immune system changes and medication effects.
• **Eligibility**: Must be over 70 years old and have specific type of lung cancer without certain gene changes.

Participants need to meet specific health conditions and are not eligible if they have certain gene mutations, untreated brain tumors, or have had certain treatments recently. It's important to discuss with a doctor to understand if this study is a good fit.